Reports Q4 revenue $109.7M, consensus $107.3M. “The continued strong performance of Axonics reflects the physician community’s preference and enthusiasm for our incontinence products,” said Raymond W. Cohen, CEO. “Revenue grew 34% in 2023, gross margin expanded to nearly 75% and Axonics generated over $50 million of adjusted EBITDA. In 2023, clinicians used Axonics therapies to treat approximately 100,000 incontinence patients globally, a testament to our mission-driven employees and their commitment to quality and teamwork. Our team is looking forward to the global impact we can make as part of Boston Scientific as we endeavor to bring these life-changing therapies to more patients than ever before.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on AXNX:
- Boston Scientific Announces Results for Fourth Quarter and Full Year 2023
- Boston Scientific price target raised to $70 from $62 at Wells Fargo
- Axonics downgraded to Hold from Buy at Needham
- Axonics downgraded to Equal Weight from Overweight at Morgan Stanley
- Axonics downgraded to Hold from Buy at Truist
Questions or Comments about the article? Write to editor@tipranks.com